Short-term and long-term effects of osteoporosis therapies.

PubWeight™: 0.98‹?› | Rank: Top 15%

🔗 View Article (PMID 25963272)

Published in Nat Rev Endocrinol on May 12, 2015

Authors

Ian R Reid1

Author Affiliations

1: Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.

Associated clinical trials:

Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis (FRAME) | NCT01575834

Articles citing this

Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment. Osteoporos Int (2016) 0.85

The effect of two doses of dried plum on bone density and bone biomarkers in osteopenic postmenopausal women: a randomized, controlled trial. Osteoporos Int (2016) 0.82

Anabolic and Antiresorptive Modulation of Bone Homeostasis by the Epigenetic Modulator Sulforaphane, a Naturally Occurring Isothiocyanate. J Biol Chem (2016) 0.79

Interplay between CaSR and PTH1R signaling in skeletal development and osteoanabolism. Semin Cell Dev Biol (2015) 0.78

A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions and Increases Bone Mass in Ovariectomized Mice. J Bone Miner Res (2016) 0.77

TGFβ-induced switch from adipogenic to osteogenic differentiation of human mesenchymal stem cells: identification of drug targets for prevention of fat cell differentiation. Stem Cell Res Ther (2016) 0.77

Anthraquinone Glycoside Aloin Induces Osteogenic Initiation of MC3T3-E1 Cells: Involvement of MAPK Mediated Wnt and Bmp Signaling. Biomol Ther (Seoul) (2016) 0.75

Treatment of Osteoporosis in Australian Residential Aged Care Facilities: Update on Consensus Recommendations for Fracture Prevention. J Am Med Dir Assoc (2016) 0.75

Impact of Calcium and Two Doses of Vitamin D on Bone Metabolism in the Elderly: A Randomized Controlled Trial. J Bone Miner Res (2017) 0.75

Spinal Compression Fracture Management: A Review of Current Treatment Strategies and Possible Future Avenues. Global Spine J (2017) 0.75

Twelve-Minute Daily Yoga Regimen Reverses Osteoporotic Bone Loss. Top Geriatr Rehabil (2015) 0.75

Raloxifene Improves Bone Mechanical Properties in Mice Previously Treated with Zoledronate. Calcif Tissue Int (2017) 0.75

Effect of whole-body vibration on reduction of bone loss and fall prevention in postmenopausal women: a meta-analysis and systematic review. J Orthop Surg Res (2016) 0.75

Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study. Br J Clin Pharmacol (2017) 0.75

Effects of combination treatment with alendronate and raloxifene on skeletal properties in a beagle dog model. PLoS One (2017) 0.75

Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Osteoporos Int (2016) 0.75

Impaired calcium sensing distinguishes primary hyperparathyroidism (PHPT) patients with low bone mineral density. Metabolism (2017) 0.75

Role of LIGHT in the pathogenesis of joint destruction in rheumatoid arthritis. World J Exp Med (2017) 0.75

Articles cited by this

(truncated to the top 100)

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81

Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57

Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ (2011) 12.63

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47

Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09

An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05

The diagnosis of osteoporosis. J Bone Miner Res (1994) 10.90

Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ (2010) 10.85

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50

Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med (1992) 9.86

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA (1999) 9.71

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57

Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med (2004) 8.86

FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25

Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47

Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med (2011) 6.44

Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet (2013) 6.19

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med (1997) 6.15

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2013) 5.76

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15

Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab (2009) 3.81

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res (2011) 3.25

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet (1997) 2.78

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int (2008) 2.74

Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues? Osteoporos Int (2014) 2.74

Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ (2010) 2.67

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med (2007) 2.64

The components of excess mortality after hip fracture. Bone (2003) 2.63

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med (2005) 2.60

Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev (2009) 2.58

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res (2011) 2.53

Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med (2012) 2.53

The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials. J Bone Miner Res (2015) 2.49

Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res (2009) 2.48

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone (2008) 2.37

Prevention of spinal osteoporosis in oophorectomised women. Lancet (1980) 2.34

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res (2010) 2.29

Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res (2012) 2.29

Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res (2003) 2.15

Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res (2011) 2.07

Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int (1994) 1.95

Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res (2010) 1.95

Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int (2007) 1.79

Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med (2014) 1.75

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res (2010) 1.74

Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab (2012) 1.74

Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc (2008) 1.70

Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med (2014) 1.70

Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res (2011) 1.70

Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int (2008) 1.68

Effect of calcium or vitamin D supplementation on vascular outcomes: a meta-analysis of randomized controlled trials. Int J Cardiol (2013) 1.63

Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial. Bone (2012) 1.62

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett (2008) 1.60

Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab (2010) 1.60

Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res (2005) 1.57

Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams. J Clin Endocrinol Metab (2013) 1.57

Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res (1986) 1.54

Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2007) 1.53

Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol (2004) 1.52

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med (2004) 1.51

The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int (2013) 1.44

Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab (2012) 1.37

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab (2009) 1.35

Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol (2011) 1.35

The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res (2012) 1.28

Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril (2009) 1.22

Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab (2014) 1.20

The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2015) 1.18

Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev (2012) 1.15

Prevalence of osteoporosis in Australian women: Geelong Osteoporosis Study. J Clin Densitom (2000) 1.13

Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop (2015) 1.11

Calcium supplements increase risk of myocardial infarction. J Bone Miner Res (2015) 1.11

Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci U S A (1997) 1.10

Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation. J Bone Miner Res (2012) 1.07

The assessment of intestinal calcium absorption using stable strontium. Calcif Tissue Int (1986) 1.03

Pharmacovigilance study of alendronate in England. Osteoporos Int (2003) 1.01

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int (2008) 0.99

Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int J Oral Maxillofac Surg (2010) 0.99

Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg (2009) 0.98

Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab (2011) 0.97

Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab (2014) 0.95

Efficacy, effectiveness and side effects of medications used to prevent fractures. J Intern Med (2015) 0.93

Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy. Menopause (2014) 0.89

Calcium risk-benefit updated--new WHI analyses. Maturitas (2013) 0.87

Osteoporosis drugs in real-world clinical practice: an analysis of persistence. Aging Clin Exp Res (2013) 0.86

[Strontium ranelate-induced DRESS syndrome]. Ann Dermatol Venereol (2010) 0.85

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med (2004) 0.81

A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record. BMJ Open (2014) 0.81

Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms. Maturitas (2013) 0.80

Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. Osteoporos Int (2014) 0.80

Stevens-Johnson syndrome due to strontium ranelate. Ann Acad Med Singapore (2011) 0.78

Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. Expert Rev Clin Pharmacol (2014) 0.75

Articles by these authors

Cardiovascular endocrinology: controversy--cardiovascular effects of calcium supplementation. Nat Rev Endocrinol (2014) 0.75